XILIO THERAPEUTICS INC (XLO) Stock Fundamental Analysis

NASDAQ:XLO • US98422T1007

0.5802 USD
-0.02 (-2.68%)
At close: Feb 13, 2026
0.5814 USD
+0 (+0.21%)
After Hours: 2/13/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

XLO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 522 industry peers in the Biotechnology industry. XLO has a bad profitability rating. Also its financial health evaluation is rather negative. XLO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • XLO had negative earnings in the past year.
  • XLO had a negative operating cash flow in the past year.
  • XLO had negative earnings in each of the past 5 years.
  • In the past 5 years XLO always reported negative operating cash flow.
XLO Yearly Net Income VS EBIT VS OCF VS FCFXLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -43.75%, XLO is in line with its industry, outperforming 55.75% of the companies in the same industry.
Industry RankSector Rank
ROA -43.75%
ROE N/A
ROIC N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XLO Yearly ROA, ROE, ROICXLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for XLO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XLO Yearly Profit, Operating, Gross MarginsXLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • XLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for XLO has been increased compared to 1 year ago.
  • The number of shares outstanding for XLO has been increased compared to 5 years ago.
  • XLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XLO Yearly Shares OutstandingXLO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XLO Yearly Total Debt VS Total AssetsXLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -4.56, we must say that XLO is in the distress zone and has some risk of bankruptcy.
  • XLO has a Altman-Z score (-4.56) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.56
ROIC/WACCN/A
WACC8.44%
XLO Yearly LT Debt VS Equity VS FCFXLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 2.20 indicates that XLO has no problem at all paying its short term obligations.
  • XLO's Current ratio of 2.20 is on the low side compared to the rest of the industry. XLO is outperformed by 73.75% of its industry peers.
  • XLO has a Quick Ratio of 2.20. This indicates that XLO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.20, XLO is doing worse than 71.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 2.2
XLO Yearly Current Assets VS Current LiabilitesXLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • XLO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.50%, which is quite impressive.
  • XLO shows a strong growth in Revenue. In the last year, the Revenue has grown by 588.40%.
EPS 1Y (TTM)67.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.27%
Revenue 1Y (TTM)588.4%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%742.51%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.10% on average over the next years. This is quite good.
  • The Revenue is expected to decrease by -10.71% on average over the next years. This is quite bad
EPS Next Y64.16%
EPS Next 2Y36.14%
EPS Next 3Y17.18%
EPS Next 5Y18.1%
Revenue Next Year492.79%
Revenue Next 2Y225.82%
Revenue Next 3Y19.19%
Revenue Next 5Y-10.71%

3.3 Evolution

XLO Yearly Revenue VS EstimatesXLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 20M 40M 60M 80M
XLO Yearly EPS VS EstimatesXLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for XLO. In the last year negative earnings were reported.
  • Also next year XLO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XLO Price Earnings VS Forward Price EarningsXLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XLO Per share dataXLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as XLO's earnings are expected to grow with 17.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.14%
EPS Next 3Y17.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for XLO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XILIO THERAPEUTICS INC

NASDAQ:XLO (2/13/2026, 8:00:02 PM)

After market: 0.5814 +0 (+0.21%)

0.5802

-0.02 (-2.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-04
Inst Owners30.02%
Inst Owner Change31.64%
Ins Owners0.66%
Ins Owner Change0.56%
Market Cap39.19M
Revenue(TTM)31.80M
Net Income(TTM)-58.49M
Analysts84
Price Target2.04 (251.6%)
Short Float %7.27%
Short Ratio4.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.91%
Min EPS beat(2)-98.02%
Max EPS beat(2)80.2%
EPS beat(4)2
Avg EPS beat(4)-74.2%
Min EPS beat(4)-287.6%
Max EPS beat(4)80.2%
EPS beat(8)4
Avg EPS beat(8)-88.69%
EPS beat(12)7
Avg EPS beat(12)-55.03%
EPS beat(16)10
Avg EPS beat(16)-38.88%
Revenue beat(2)1
Avg Revenue beat(2)-0.6%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)1.3%
Revenue beat(4)1
Avg Revenue beat(4)-20.89%
Min Revenue beat(4)-48.27%
Max Revenue beat(4)1.3%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)0%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-14.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)17.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.23
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.47
BVpS-0.12
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.75%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.93%
Cap/Sales 1.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.2
Quick Ratio 2.2
Altman-Z -4.56
F-Score6
WACC8.44%
ROIC/WACCN/A
Cap/Depr(3y)42.95%
Cap/Depr(5y)81.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.27%
EPS Next Y64.16%
EPS Next 2Y36.14%
EPS Next 3Y17.18%
EPS Next 5Y18.1%
Revenue 1Y (TTM)588.4%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%742.51%
Revenue Next Year492.79%
Revenue Next 2Y225.82%
Revenue Next 3Y19.19%
Revenue Next 5Y-10.71%
EBIT growth 1Y31.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.76%
EBIT Next 3Y9.46%
EBIT Next 5Y12.01%
FCF growth 1Y76.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.64%
OCF growth 3YN/A
OCF growth 5YN/A

XILIO THERAPEUTICS INC / XLO FAQ

What is the ChartMill fundamental rating of XILIO THERAPEUTICS INC (XLO) stock?

ChartMill assigns a fundamental rating of 1 / 10 to XLO.


Can you provide the valuation status for XILIO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to XILIO THERAPEUTICS INC (XLO). This can be considered as Overvalued.


Can you provide the profitability details for XILIO THERAPEUTICS INC?

XILIO THERAPEUTICS INC (XLO) has a profitability rating of 0 / 10.


Can you provide the financial health for XLO stock?

The financial health rating of XILIO THERAPEUTICS INC (XLO) is 3 / 10.


Can you provide the expected EPS growth for XLO stock?

The Earnings per Share (EPS) of XILIO THERAPEUTICS INC (XLO) is expected to grow by 64.16% in the next year.